Carmat (EPA:ALCAR) Full Year 2023 Results
Key Financial Results
- Revenue: €12.6m (up by €12.1m from FY 2022).
- Net loss: €53.9m (flat on FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Carmat Revenues Disappoint
Revenue missed analyst estimates by 65%.
Looking ahead, revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in France.
Performance of the French Medical Equipment industry.
The company's shares are down 2.5% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Carmat has 4 warning signs (and 1 which is potentially serious) we think you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALCAR
Carmat
Designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally.
Moderate with limited growth.
